Back to today’s briefing

Story perspectives

Eli Lilly Dominates GLP-1 Market, Outpacing Novo Nordisk

11/23/2025

26 2

Summary

Story summary

Eli Lilly and Company leads the GLP-1 market, driven by tirzepatide, which earned $24.8 billion in 2025.
Eli Lilly's pipeline includes orforglipron, an oral GLP-1, and retatrutide, a three-hormone approach.
Novo Nordisk A/S has seen its market share fall from 55.7% to 49.3% amid competition and slower sales, while expanding lower-priced versions of its drugs.
Despite Novo Nordisk's efforts, Eli Lilly is expected to maintain leadership.

1 of 1

Story summary

Eli Lilly and Company leads the GLP-1 market, driven by tirzepatide, which earned $24.8 billion in 2025.
Eli Lilly's pipeline includes orforglipron, an oral GLP-1, and retatrutide, a three-hormone approach.
Novo Nordisk A/S has seen its market share fall from 55.7% to 49.3% amid competition and slower sales, while expanding lower-priced versions of its drugs.
Despite Novo Nordisk's efforts, Eli Lilly is expected to maintain leadership.